Loading...

Evotec SE

EVONASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$3.15
$-0.08(-2.48%)
U.S. Market opens in 8h 28m

Evotec SE Fundamental Analysis

Evotec SE (EVO) shows weak financial fundamentals with a PE ratio of -9.26, profit margin of -13.19%, and ROE of -11.54%. The company generates $0.8B in annual revenue with weak year-over-year growth of 1.99%.

Key Strengths

Cash Position42.53%
PEG Ratio-0.19
Current Ratio2.07

Areas of Concern

ROE-11.54%
Operating Margin-8.68%
We analyze EVO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 4.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
4.7/100

We analyze EVO's fundamental strength across five key dimensions:

Efficiency Score

Weak

EVO struggles to generate sufficient returns from assets.

ROA > 10%
-5.83%

Valuation Score

Excellent

EVO trades at attractive valuation levels.

PE < 25
-9.26
PEG Ratio < 2
-0.19

Growth Score

Weak

EVO faces weak or negative growth trends.

Revenue Growth > 5%
1.99%
EPS Growth > 10%
-1.36%

Financial Health Score

Excellent

EVO maintains a strong and stable balance sheet.

Debt/Equity < 1
0.55
Current Ratio > 1
2.07

Profitability Score

Weak

EVO struggles to sustain strong margins.

ROE > 15%
-1154.41%
Net Margin ≥ 15%
-13.19%
Positive Free Cash Flow
No

Key Financial Metrics

Is EVO Expensive or Cheap?

P/E Ratio

EVO trades at -9.26 times earnings. This suggests potential undervaluation.

-9.26

PEG Ratio

When adjusting for growth, EVO's PEG of -0.19 indicates potential undervaluation.

-0.19

Price to Book

The market values Evotec SE at 1.18 times its book value. This may indicate undervaluation.

1.18

EV/EBITDA

Enterprise value stands at -26.66 times EBITDA. This is generally considered low.

-26.66

How Well Does EVO Make Money?

Net Profit Margin

For every $100 in sales, Evotec SE keeps $-13.19 as profit after all expenses.

-13.19%

Operating Margin

Core operations generate -8.68 in profit for every $100 in revenue, before interest and taxes.

-8.68%

ROE

Management delivers $-11.54 in profit for every $100 of shareholder equity.

-11.54%

ROA

Evotec SE generates $-5.83 in profit for every $100 in assets, demonstrating efficient asset deployment.

-5.83%

Following the Money - Real Cash Generation

Operating Cash Flow

Evotec SE generates limited operating cash flow of $-11.77M, signaling weaker underlying cash strength.

$-11.77M

Free Cash Flow

Evotec SE generates weak or negative free cash flow of $-92.08M, restricting financial flexibility.

$-92.08M

FCF Per Share

Each share generates $-0.26 in free cash annually.

$-0.26

FCF Yield

EVO converts -9.61% of its market value into free cash.

-9.61%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.26

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.19

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.18

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.22

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.55

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.07

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.12

vs 25 benchmark

ROA

Return on assets percentage

-0.06

vs 25 benchmark

ROCE

Return on capital employed

-0.05

vs 25 benchmark

How EVO Stacks Against Its Sector Peers

MetricEVO ValueSector AveragePerformance
P/E Ratio-9.2628.81 Better (Cheaper)
ROE-11.54%643.00% Weak
Net Margin-13.19%-44312.00% (disorted) Weak
Debt/Equity0.550.36 Weak (High Leverage)
Current Ratio2.074.50 Strong Liquidity
ROA-5.83%-17799.00% (disorted) Weak

EVO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evotec SE's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

50.76%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-533.98%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-63.55%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ